Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 11;8(10):e76189.
doi: 10.1371/journal.pone.0076189. eCollection 2013.

The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India

Dorai Deepa  1 , Shanta Achanta, Jyoti Jaju, Koteswara Rao, Rani Samyukta, Mareli Claassens, Ajay M V Kumar, Vishnu Ph
Affiliations

The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India

Dorai Deepa et al. PLoS One. .

Abstract

Background: Multi drug resistant and rifampicin resistant TB patients in India are treated with the World Health Organization (WHO) recommended standardized treatment regimens but no guidelines are available for the management of isoniazid (INH) resistant TB patients. There have been concerns that the standard eight-month retreatment regimen being used in India (2H3R3Z3E3S3/1H3R3Z3E3/5H3R3E3; H-Isoniazid; R-Rifampicin; Z-Pyrazinamide; E-Ethambutol; S-Streptomycin) may be inadequate to treat INH resistant TB cases and leads to poor treatment outcomes. We aimed to assess if INH resistance is associated with unfavorable treatment outcomes (death, default, failure and transferred out) among a cohort of smear positive retreatment TB patients registered in three districts of Andhra Pradesh, India.

Methods: We conducted a retrospective record review of all smear positive retreatment TB patients without rifampicin resistance registered during April-December 2011.

Results: Of 1,947 TB patients, 1,127 (58%) were tested with LPA-50 (4%) were rifampicin resistant, 933 (84%) were sensitive to INH and rifampicin and 144 (12%) were INH resistant. Of 144 INH resistant cases, 64 (44%) had poor treatment outcomes (25 (17%) default, 22 (15%) death, 12 (8%) failure and 5 (3%) transfer out) as compared to 287 (31%) among INH sensitive cases [aRR 1.46; 95%CI (1.19-1.78)].

Conclusion: Our study confirms that INH resistance is independently associated with unfavorable treatment outcomes among smear positive retreatment TB patients, indicating that the current treatment regimen may be inadequate. These findings call for an urgent need for randomized controlled trials to discover the most effective treatment regimen for managing INH resistant TB.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Line Probe Assay (LPA) testing and results among retreatment smear positive tuberculosis patients registered in three districts of Andhra Pradesh, India, April 2011 to March 2012.
See this image and copyright information in PMC

References

    1. World Health Organization (2008) The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world Report No. 4 World Health Organization Document WHO/HTM/TB/2008.394: 1-120
    1. World Health Organization (2010) Treatment of tuberculosis: guidelines for national programmes. fourth edition. World Health Organization Document WHO/HTM/TB/2009.420: 1-147
    1. Central TB Division (2011) Managing the RNTCP in your area - A training course ( Modules 1-4) and (Modules 1-9). Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Available: http://www.tbcindia.nic.in/documents.asp#. Accessed 2013 June 12.
    1. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization Document WHO/HTM/TB/2008.402: 1-247.
    1. Vijay S, Balasangameshwara VH, Jagannatha PS, Saroja VN, Shivashankar D et al. (2002) Re-treatment outcome of smear positive tuberculosis cases under DOTS in Bangalore City. Indian J Tuberc 49: 195-204.

Publication types